Abstract

This review provides a thorough examination of opioid analgesics, covering their chemical structure, mechanism of action, classification, pharmacokinetics, and pharmacodynamics. Beginning with an exploration of the chemical structure of morphine and its analogues, the review elucidates the structural features critical for opioid activity, highlighting the diverse chemical scaffolds that underpin this class of medications. Subsequently, the review delves into the intricate mechanisms of action through which opioids exert their analgesic effects, focusing on their interactions with the mu, delta, and kappa opioid receptors within the central and peripheral nervous systems. Furthermore, the review provides a comprehensive classification of opioid analgesics based on their chemical structure, receptor selectivity, and clinical properties, delineating between natural, semi-synthetic, and synthetic opioids, as well as agonists, partial agonists, and antagonists. In addition, the review examines the pharmacokinetic properties of opioid analgesics, encompassing absorption, distribution, metabolism, and elimination pathways, and explores how individual pharmacokinetic profiles influence clinical dosing and therapeutic outcomes. Moreover, the review delves into the dynamic pharmacodynamics of opioids, elucidating dose response relationships, onset and duration of action, and factors influencing inter-individual variability in response to opioid therapy. Finally, the review underscores the clinical implications of opioid pharmacology, emphasizing the importance of judicious prescribing practices, individualized treatment approaches, and multidisciplinary collaboration in optimizing pain management while mitigating the risks of opioid related adverse effects, tolerance, dependence, and misuse.

• 1.   Graham L Patrick. The opioid analgesics. In: An Introduction to Medicinal Chemistry. Oxford: Oxford University Press; 2013. p. 632-658.
• 2.   Hasan Pathan, John Williams. Basic opioid pharmacology: an update. British Journal of Pain 2012;6(1):11-16.
• 3.   Health Promotion. PCD provides an open exchange of information and knowledge among researchers.
• 4.   Shipton EA, Shipton EE, Shipton AJ. A Review of the Opioid Epidemic: What Do We Do About It?”. Pain and Therapy 2008;7(1):23–36.
• 5.   World Health Organization. Opioid overdose. August 4, 2021. Archived from the original on December 1, 2014.
• 6.   Ambekar A, Agrawal A, Rao R, et al. Magnitude of Substance Use in India. New Delhi: Ministry of Social Justice and Empowerment, Government of India 2019.
• 7.   V. Alagarswamy. Narcotic Analgesics. In: Textbook of Medicinal Chemistry: Elsevier; 2010. p. 247-285.
• 8.   Stein, Christoph MD, Priv Doz. Peripheral Mechanisms of Opioid Analgesia. Anesthesia & Analgesia 1993. 76(1);182-191.
• 9.   Spetea, M.; Schmidhammer, H. Recent Chemical and Pharmacological Developments on 14-OxygenatedN-methylmorphinan-6-ones. Molecules 2021, 26, 5677.
• 10.   Rita T, Agostino M, Carmela P, Lorella P. Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review. European Journal of Medicinal Chemistry, Volume 148, 2018. 410-422.
• 11.   KD Tripathi. Opioid Analgesics and Antagonists. In: Essentials of Medical Pharmacology. Jaypee Brothers Medical Publishers (P) Ltd.; 2013.469-485.
• 12.   Rajiv Balyan, David Hahn, Henry Huang, Vidya Chidambaran. Pharmacokinetic and pharmacodynamic considerations in developing a response to the opioid epidemic. Expert Opin Drug Metab Toxicol. 2020 Feb;16(2):125-141.
• 13.   Andrea M Trescot MD, Sukdeb Datta MD, Marion Lee MD, Hans Hansen MD. Opioid Pharmacology. Pain Physician 2008;11:S133-S153.
• 14.   R.T. Jones. Euphoria vs. cocaine plasma concentrations after nasal administration (20% solution). In. C.N. Chiang, R.L. Hawks (eds.), NIDA Research Monograph 99 (Research Findings on Smoking of Abused Substances); 1990. p. 30–41.
• 15.   McCleane G, Smith H. Opioids for persistent noncancer pain. Med Clin N Am 2007;(91):177-197.
• 16.   Corbett AD, Henderson G, McKnight AT, Paterson SJ. 75 years of opioid research: the exciting but vain quest for the Holy Grail. British J Pharmacology 2006;147:S153-S162.
• 17.   Pan Z, Hirakawa N, Fields HL. A cellular mechanism for the bidirectional pain-modulating actions of orphanin FQ/nociceptin. Neuron May 26; 515–522.
• 18.   Dolin SJ, Cashman JN & Bland JM. Effectiveness of acute postoperative pain management: I. Evidence from published data. British Journal of Anaesthesia 2002; 89:409-23.
• 19.   John M Swegle, Craig Logemann. Management of Common Opioid Induced Adverse Effects. Am Fam Physician 2006;74(8):1347-1354.
• 20.   Mahmoud Reza Khansari, Masour Reza Sohrabi, Farhad Zamani. The Usage of Opioids and their Adverse Effects in Gastrointestinal Practice: A Review. Middle East J Dig Dis 2013 Jan;5(1):5-16.
• 21.   Side effects of opioids. Faculty of Pain Medicine of the Royal College of Anaesthetists. https://fpm. ac.uk/opioids-aware-clinical-use-opioids/sideeffects-opioids#:~:text=Most%20commom%20 side%20effects%20are,extremely%20common%20 with%20opioid%20therapy.
• 22.   World Health Organization. Opioid Overdose. 29 August 2023.
• 23.   Center for Behavioral Health Statistics and Quality. National Survey on Drug Use and Health (NSDUH): methodological summary and definitions. Accessed October 7, 2022.
• 24.   National Institute on Drug Abuse. The science of drug use and addiction: the basics.
• 25.   Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013-2019.2021;70:202–207.

Data Sharing Statement

Funding